Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval entities : Teva pharmaceutical industries ltd save search
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Published: 2024-04-16 (Crawled : 21:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
stelara fda biosimilar approval teva
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
Published: 2024-02-24 (Crawled : 04:20) - globenewswire.com
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
| Email alert
Add to watchlist
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
simlandi first biosimilar approval teva
STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara
Published: 2024-01-10 (Crawled : 09:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: -0.72%
H: 1.77%
C: -1.53%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: -0.66%
H: 0.71%
C: 0.17%
first biosimilar approval stelara
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
Published: 2023-11-17 (Crawled : 16:00) - biospace.com/
TEVA | $12.78 -3.03% -0.24% 9M
|
Health Technology
|
| O: 0.91%
H: 2.6%
C: 2.38%
HALO M | $37.84 -0.47% -0.48% 790K
|
Health Technology
|
| O: 0.94%
H: 1.8%
C: 0.1%
forteo approval teva
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
Published: 2023-09-25 (Crawled : 08:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: 1.24%
H: 4.25%
C: -0.67%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: 1.16%
H: 1.98%
C: -0.38%
avt04 stelara biosimilar japan approval
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
Published: 2023-08-29 (Crawled : 09:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: -0.93%
H: 3.75%
C: 2.39%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: 0.55%
H: 2.24%
C: 0.92%
avt02 approval egypt
Diffuse large B-cell lymphoma (DLBCL) therapeutics market size to increase by USD 2,061.88 million between 2022 and 2027; Growth driven by increasing approval of therapeutics - Technavio
Published: 2023-03-10 (Crawled : 23:00) - prnewswire.com
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
| Email alert
Add to watchlist
CTIC | $9.09 0.05% 11M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
| Email alert
Add to watchlist
ADCT | $4.76 -4.03% 0.0% 280K
|
Health Technology
| Email alert
Add to watchlist
approval therapeutics growth market
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
Published: 2023-01-24 (Crawled : 10:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: -1.34%
H: 2.21%
C: 0.85%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: -1.04%
H: 0.0%
C: -2.73%
avt02 approval
Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan
Published: 2022-10-17 (Crawled : 10:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: 0.44%
H: 7.05%
C: 2.64%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: 2.74%
H: 0.89%
C: 0.0%
candidate biosimilar japan application approval
Neurologic Disorders Therapeutics Market Size to Grow by USD 33.46 billion, Approval Of Novel Drugs to Boost Market Growth - Technavio
Published: 2022-08-03 (Crawled : 04:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.8%
H: 0.2%
C: 0.0%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
NPCE | News S | $14.07 2.33% 2.27% 65K
|
Manufacturing
|
| O: 0.52%
H: 3.71%
C: -2.93%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.11%
H: 0.31%
C: -0.34%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.29%
H: 0.24%
C: -0.58%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: 0.41%
H: 3.35%
C: 1.71%
ACAD | News | $17.08 -0.64% -0.64% 990K
|
Health Technology
|
| O: 2.47%
H: 2.8%
C: -2.67%
approval therapeutics growth market
Global Pharmaceutical API Manufacturing Market Report 2022-2030: Stringent Regulations for Approval of Pharmaceutical Drugs Restraining Growth
Published: 2022-04-12 (Crawled : 17:00) - prnewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -0.86%
H: 1.21%
C: 1.21%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.16%
H: 0.22%
C: 0.22%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.48%
H: 0.09%
C: -0.68%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.77%
H: 0.99%
C: 0.49%
ALB | News | $111.8 -2.26% 0.63% 2.2M
|
Process Industries
|
| O: 1.31%
H: 2.06%
C: -1.76%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.31%
H: 0.74%
C: -1.18%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -3.25%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -2.32%
H: 0.43%
C: -0.55%
report approval growth market drug
CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Published: 2022-01-31 (Crawled : 07:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: -2.34%
dupixent approval chmp children
FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
Published: 2021-10-20 (Crawled : 22:00) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.08%
H: 0.41%
C: 0.41%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.31%
H: 1.14%
C: 0.87%
fda children approval dupixent
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.